UK Markets close in 2 hrs 29 mins

MorphoSys AG (MOR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.49+1.04 (+23.37%)
At close: 04:00PM EDT
5.60 +0.11 (+2.00%)
Pre-market: 08:43AM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • D
    As bad as the whole german economy.....10Euros at the end of september
  • s
    A 4 year path to profitability.
  • M
    Buyout before year end.
  • M
    Trading action like harbinger of a buyout.
  • M
    Lowballing + badmouthing = in play for M&A
  • M
    Morphosys job openings. see below, yet the stock trading as for bankruptcy. Share price BEING lowballed for
  • D
    220Euros going 10 and less
  • M
    Don't let the MM fool you, it's green in London & in Germany.
  • D
    Bad co....stay away
  • M
    $CYDY conversation
    My several thoughts about $HGEN and recently announced participation in the BET trial ("big effect trial") funded by NIAID.
    1) Lenzilumab selection was based on the compassionate use data, not on the data from the ongoing ph3 trial. This might implicate that probably no interim report data from the ongoing ph3 trial is available, which in turn might implicate that HGEN has problems with fast patients enrolment (similarly to CYDY).
    2) It is strange why now a new ph3 trial is started (with 100 patients in each arm) when another ph3 trial (with 300 patients) is already running (started already in May). The novelty regarding this new trial is that a combination of remdesivir+lenzilumab is tested as well.
    3) Actually I do not understand why this BET trial with lenzilumab (and not only with lenzilumab) has not started several months ago as soon as promising data from compassionate use has been available. At the same time (around April-May) several other arms of such trial could have been added, including leronlimab from $CYDY (targeting CCR5) or other monoclonal antibodies targeting the same cytokine (GM-CSF) as lenzilumab - i.e. mavrilimumab from $KNSA, otilimab from $MOR / $GSK, and gimsilumab from Roivant.
    4) Of course it is a good news for HGEN that NIH is interested in lenzilumab and a bad news for CYDY if leronlimab has not been considered (but this might change). But anyway, if the data from the current leronlimab trials is positive (especially in case that the S/C trial is halted by the ethical committee), there is surely no need to start a new, NIAID funded trial.
  • G
    Grifone Rampante
    Hi guys, I have a fairly trivial question, I hope someone can answer me: Morphosys is buying Constellation Pharma, currently Morphosys has 34M outstanding shares, if it bought Constellation Pharma (60M outstanding shares) Morph's outstanding shares would become 94M or it works like this only in mergers? With 34M outstanding shares Mor at these prices is highly undervalued because it has a market cap of one and a half billion, if they become 94, however, the stock could end in the 20's. Let me know, because if the shares remain 34M, I want to buy
  • B
    $EXEL conversation
    If $EXEL is looking to diversify & add molecules in the clinic quickly w/ premier bi-specific Ab, then it needs to look into collaboration w/ $XNCR .Their collaboration with Genentech $RHHB Janssen $amgn $NVS
    MDAnderson morphosys $MOR Alexion $alxn Astellas (Japan) validates XNCR's technology. It's at least worth a look and there could be hugely beneficial arrangements for both parties. Xencor has very rich pipeline already and I am sure would be happy to have a partner take over some of these advanced molecules as well as with their excellent and much sought after bi-specific technology and premiere engineering platform, have many in early preclinical development. Doesn't mean EXEL needs to jump in but some due diligence and potential partnership would be time well spent. Bi-specific technology of biologics would nicely complement Exelixis' small molecule and ADC pipeline and collaborations.
  • E
    MOR is going down almost every day. It will take several years to recover - if it will ever recover.Dont think that the promissing 2-3 phase data can turn this around. The bearish momentum is too strong. The shortseller have even increased their positions.Most likely we will see prices below 20#$%$ And even then it would make no sense to averange down. I should just cut my losses and move on.
  • C
    Today may have been the bottom. MOR has a market cap of 1.2B yet they spent 1.7B on Constellation Pharma. This doesn't make sense to me bearing in mind their current licensed products + their own pipeline.
  • H
    According to chart this looks like is ready to reverse the trend. Trading Central have forecasted a very strong bullish evidence for short and medium term. It might be a good time to load...